Abstract: Pharmaceutical composition of antineoplastic and anti-tumor action, and method of obtaining it, wherein said composition comprises structured lipid nanoparticles that are between 0.1 nm and 100 nm in diameter, spheroidal in shape and contain particles of one or more active substances for the treatment of diseases produced by tripanosomes and for the treatment of tumors of neural origin, and at least one coupling of two fatty acids consisting of a saturated fatty acid or semi-solid lipid at the temperature between 19° C. and 21° C. and an unsaturated or liquid fatty acid at the temperature between 19° C. and 21° C. and in turn the method of obtaining finally contains the nanoparticles of one or more active substances for trypanosomiasis in colloidal suspension, the Z potential ranges from ?30 to +30, preferably +8, the particles measured by Z-sizer and ultramicroscopy have from 0.1 nanometers to 100 nanometers, preferably 1 nanometer in diameter and spheroidal shape.

Abstract: The present invention relates to a method for maintaining a healthy bone structure by administering to a patient a bone health promoting effective amount of a medicament containing 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid, any of its soluble salts or any of its hydrates.

Abstract: This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average±1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bishphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again.